Edition:
United States

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

67.26USD
16 Feb 2018
Change (% chg)

$3.51 (+5.51%)
Prev Close
$63.75
Open
$63.75
Day's High
$71.22
Day's Low
$63.70
Volume
767,562
Avg. Vol
358,773
52-wk High
$71.22
52-wk Low
$46.65

Latest Key Developments (Source: Significant Developments)

Alkermes PLC Reports Q4 Non-Gaap Earnings Per Share $0.31
Wednesday, 14 Feb 2018 07:00am EST 

Feb 14 (Reuters) - Alkermes Plc ::REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED DEC. 31, 2017 AND PROVIDES FINANCIAL EXPECTATIONS FOR 2018.Q4 NON-GAAP EARNINGS PER SHARE $0.31.Q4 REVENUE $275.4 MILLION.SEES FY 2018 NON-GAAP LOSS PER SHARE $0.03 TO $0.23.SEES FY 2018 LOSS PER SHARE $1.61 TO $1.81.Q4 GAAP LOSS PER SHARE $0.06.COMPANY EXPECTS TOTAL REVENUES TO RANGE FROM $975 MILLION TO $1.025 BILLION IN 2018.COMPANY EXPECTS CAPITAL EXPENDITURES TO RANGE FROM $80 MILLION TO $90 MILLION IN 2018.Q4 EARNINGS PER SHARE VIEW $0.23, REVENUE VIEW $252.9 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $999.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Alkermes Submits NDA To U.S. FDA For ALKS 5461 FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER
Wednesday, 31 Jan 2018 02:01pm EST 

Jan 31 (Reuters) - Alkermes Plc ::ALKERMES SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER.  Full Article

Primecap Management Co Reports A 11.35 Pct Passive Stake In Alkermes
Tuesday, 5 Dec 2017 12:08pm EST 

Dec 5 (Reuters) - Alkermes Plc ::PRIMECAP MANAGEMENT CO REPORTS A 11.35 PCT PASSIVE STAKE IN ALKERMES PLC <<>> AS OF NOV 30 - SEC FILING.  Full Article

Alkermes Expects 2017 Non-GAAP Income Of $0.03 To $0.22/Shr
Monday, 27 Nov 2017 07:23am EST 

Nov 27 (Reuters) - Alkermes Plc ::ALKERMES PLC- NOW EXPECTS 2017 TOTAL REVENUES TO RANGE FROM $870 MILLION TO $900 MILLION‍​ - SEC FILING.ALKERMES PLC- NOW EXPECTS 2017 NON-GAAP DILUTED INCOME PER SHARE OF $0.03 TO $0.22.ALKERMES PLC - EXPECTS 2017 GAAP BASIC AND DILUTED LOSS PER SHARE OF $0.91 TO $1.10‍​.  Full Article

Alkermes’ NDA for ARISTADA accepted for filing by U.S. FDA
Thursday, 16 Nov 2017 07:00am EST 

Nov 16 (Reuters) - Alkermes Plc ::Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® accepted for filing by U.S. FDA.Says FDA issued target action date for Aripiprazole Lauroxil Nanocrystal Dispersion​ NDA of June 30, 2018 under PDUFA.  Full Article

ALKERMES INITIATES CLINICAL STUDY EVALUATING ARISTADA, INVEGA SUSTENNA FOR SCHIZOPHRENIA
Thursday, 26 Oct 2017 07:02am EDT 

Oct 26 (Reuters) - Alkermes Plc :ALKERMES TO INITIATE NEW CLINICAL STUDY EVALUATING ARISTADA® AND INVEGA SUSTENNA® FOR THE TREATMENT OF SCHIZOPHRENIA.ALKERMES PLC - ‍PHASE 3B STUDY WILL ASSESS INVESTIGATIONAL PRODUCT DESIGNED FOR INITIATION ONTO ARISTADA​.ALKERMES PLC - ‍EFFICACY AND SAFETY OF TWO-MONTH ARISTADA COMPARED TO MARKET LEADER INVEGA SUSTENNA WILL ALSO BE EVALUATED IN TRIAL​.  Full Article

ALKERMES PLC REPORTS ‍Q3 GAAP LOSS PER SHARE OF $0.24
Thursday, 26 Oct 2017 07:00am EDT 

Oct 26 (Reuters) - Alkermes Plc ::ALKERMES PLC REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS.‍Q3 TOTAL REVENUES INCREASED 21% YEAR-OVER-YEAR TO $217.4 MILLION​.‍Q3 GAAP LOSS PER SHARE OF $0.24​.‍Q3 NON-GAAP EARNINGS PER SHARE OF $0.03​.‍COMPANY UPDATES FINANCIAL EXPECTATIONS FOR 2017​.Q3 EARNINGS PER SHARE VIEW $-0.01, REVENUE VIEW $231.0 MILLION -- THOMSON REUTERS I/B/E/S.‍NOW EXPECTS 2017 TOTAL REVENUES TO RANGE FROM $850 MILLION TO $880 MILLION​.‍NOW EXPECTS 2017 BASIC AND DILUTED LOSS PER SHARE OF $1.04 TO $1.23​.‍NOW EXPECTS 2017 CAPITAL EXPENDITURES TO RANGE FROM $50 MILLION TO $60 MILLION, REDUCED FROM $70 MILLION TO $80 MILLION​.FY2017 EARNINGS PER SHARE VIEW $-0.04, REVENUE VIEW $894.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Alkermes PLC says ‍initiates rolling submission of ALKS 5461 NDA to U.S. FDA
Monday, 21 Aug 2017 07:00am EDT 

Aug 21 (Reuters) - Alkermes Plc : :Alkermes PLC- ‍Initiates rolling submission of ALKS 5461 NDA to U.S. FDA; Expects to complete submission of NDA for medicine by year-end 2017​.  Full Article

Alkermes qtrly gaap loss per share $0.28
Thursday, 27 Jul 2017 07:00am EDT 

July 27 (Reuters) - Alkermes Plc ::Alkermes Plc reports second quarter 2017 financial results.Qtrly gaap loss per share $0.28.Qtrly non-gaap earnings per share of $0.01.Qtrly revenues increased 12% year-over-year to $218.8 million.Alkermes Plc says reiterates its financial expectations for 2017.  Full Article

Alkermes announces positive preliminary topline results
Thursday, 29 Jun 2017 04:00pm EDT 

June 29 (Reuters) - Alkermes Plc ::Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia.Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia.Alkermes Plc - study met prespecified primary endpoint.Alkermes - ALKS 3831 demonstrating statistically significant reductions from baseline in positive and negative syndrome scale scores versus placebo.Alkermes Plc - study also met its key secondary endpoint.Alkermes Plc - study met prespecified primary endpoint, with ALKS 3831.Alkermes - enlighten-2, six-month phase 3 study evaluating weight gain profile of olanzapine compared to ALKS 3831, is ongoing with data expected in 2018.Alkermes Plc - ALKS 3831 demonstrated statistically significant reductions from baseline in positive and negative syndrome scale scores compared to placebo.  Full Article

BRIEF-Alkermes PLC Reports Q4 Non-Gaap Earnings Per Share $0.31

* REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED DEC. 31, 2017 AND PROVIDES FINANCIAL EXPECTATIONS FOR 2018